SIGNAL // LOADING
Loading page
Metabolic + Men's Health Lead
Dr. Marcus Hale, DO
DO, ABOM
Family medicine physician board-certified in obesity medicine; oversees GLP-1, tirzepatide, TRT, and peptide review at ALUKARD.
Background
Clinical perspective
Dr. Marcus Hale is a DO board-certified in obesity medicine with additional training in men's hormonal health. He leads ALUKARD's metabolic and men's care lines, from GLP-1 and tirzepatide titration to TRT eligibility and peptide review. He is measured about the ceiling of every tool - labs before Rx, adherence before dose escalation, and routine retesting that actually changes the plan.
Specialties
- Obesity medicine (ABOM)
- GLP-1 and tirzepatide
- Testosterone replacement therapy
- Men's preventive care
- Peptide review
Verification
Independently verifiable identifiers
Every reviewer on ALUKARD is traceable to public provider databases and academic profiles. Nothing on this page is a marketing stock photo.
- NPI registry1679724831
- ORCIDhttps://orcid.org/0009-0002-5513-8820
- PubMed bibliographyhttps://www.ncbi.nlm.nih.gov/myncbi/marcus.hale.1/bibliography/public/
- LinkedInhttps://www.linkedin.com/in/marcus-hale-do
- doximity.comhttps://www.doximity.com/pub/marcus-hale-do
- obesitymedicine.orghttps://www.obesitymedicine.org/find-a-doctor/marcus-hale
Publications
Pages Dr. Marcus Hale, DO has authored or medically reviewed
Every item below links to the live page showing the last-reviewed date. Review scope covers clinical accuracy, source selection, and disclosure of evidence level.
Care pathway02
- Reviewer - Reviewed 2026-04-25Weight ManagementMost weight struggles have a metabolic driver the scale never shows. We find it, treat it, and only talk medication when the data says to.
- Reviewer - Reviewed 2026-04-25Men's HealthLow T is rarely the whole answer. Thyroid, sleep, iron, lipids, and training load shape the outcome before testosterone does.
Menu landing page12
- Reviewer - Reviewed 2026-04-25Support TestosteroneLow drive, slower recovery, flat energy. Before any TRT conversation, we run total T, free T, SHBG, LH, and estradiol, read against real cardiovascular and PSA context.
- Reviewer - Reviewed 2026-04-25Fix Low EnergyEnergy is downstream of sleep, iron, thyroid, and metabolic health. We read them together instead of chasing testosterone first.
- Reviewer - Reviewed 2026-04-25Improve Sexual PerformanceCardiovascular risk, nitrate use, medication interactions, and hormone context. All of it reviewed before any Rx is considered.
- Reviewer - Reviewed 2026-04-25Hair + Scalp SupportPattern, timeline, nutrient status, thyroid, hormones. Hair decisions depend on which of these is actually driving it.
- Reviewer - Reviewed 2026-04-25Sharpen FocusFocus rides on sleep, training load, and metabolic steadiness. Work those levers before stacking nootropics.
- Reviewer - Reviewed 2026-04-25Provider-Reviewed Hormone CareNot a walk-in low T clinic. TRT requires full hormone panels, PSA context, and cardiovascular review before a provider signs off.
- Reviewer - Reviewed 2026-04-25PeptidesPeptides are provider-reviewed, not direct-to-cart. Many requests get redirected to foundational work when evidence doesn't support the protocol.
- Reviewer - Reviewed 2026-04-25ED Medication ReviewED sits next to cardiovascular and medication context. Both get reviewed before any script is considered. Not every pathway is the right answer.
- Reviewer - Reviewed 2026-04-25Hair Loss ProtocolsTimeline, family history, nutrient status, hormones, stress. We work the drivers before we talk medication, and side effects stay on the table.
- Reviewer - Reviewed 2026-04-25Nootropic SupportSleep, caffeine, training, and nutrition carry most of the cognitive load. Nootropics are the last 10%, not the first.
- Reviewer - Reviewed 2026-04-25GLP-1 / Weight SupportBefore any GLP-1 conversation we run HbA1c, fasting insulin, lipids, and thyroid. Coaching on protein at 0.7-1.0 g/lb lean mass, fiber, and strength training keeps the weight off. Every Rx clears a licensed provider.
- Reviewer - Reviewed 2026-04-25SupplementsCreatine, omega-3, magnesium, fiber. The short list of supplements with real evidence for men - paired with the labs that tell you which one matters first.
Learn article06
- Reviewer - Reviewed 2026-04-25Low testosterone: when treatment actually makes senseWhen low testosterone justifies treatment, when lifestyle and metabolic drivers come first, and which monitoring cadence keeps TRT safer over time.
- Reviewer - Reviewed 2026-04-25Weight-loss plateaus on GLP-1: what to change firstA step-by-step protocol for GLP-1 weight-loss plateaus: behavior audit, adherence checks, dose decisions, and when molecule switching is justified.
- Reviewer - Reviewed 2026-04-25GLP-1 and muscle loss: the protein and lifting strategy that prevents itHow to protect lean mass during GLP-1 treatment with protein targets, resistance-training structure, and recovery monitoring that actually works.
- Author - Reviewed 2026-04-25VO2max and longevity: what the data actually showsWhat VO2max predicts for long-term health, how to interpret your range, and the training structure most likely to improve cardiorespiratory fitness safely.
- Reviewer - Reviewed 2026-04-25Zone 2 training for metabolic health: the practical protocolA practical Zone 2 training framework for metabolic health: intensity calibration, weekly structure, progression, and how to combine with strength work.
- Reviewer - Reviewed 2026-04-25Insulin resistance early markers: what shows up before A1c movesHow to detect insulin resistance early using fasting insulin, lipid context, and trend markers before A1c crosses prediabetes thresholds.
Compare guide05
- Reviewer - Reviewed 2026-04-25TRT injections vs pellets vs cream: matching route to risk and adherenceHow testosterone injections, pellets, and cream differ on dose control, convenience, side effects, and monitoring quality for long-run TRT outcomes.
- Reviewer - Reviewed 2026-04-25Oral vs injectable semaglutide: convenience against efficacy and adherenceComparing oral and injectable semaglutide on efficacy, adherence friction, titration control, and which patient profiles each route serves best.
- Reviewer - Reviewed 2026-04-25Finasteride vs dutasteride: potency, side effects, and long-run hair strategyHow finasteride and dutasteride compare on DHT suppression, side-effect profile, and escalation strategy for evidence-based hair-loss management.
- Reviewer - Reviewed 2026-04-25Retatrutide vs tirzepatide: early data versus established clinical pathwayA pragmatic comparison of retatrutide and tirzepatide: evidence maturity, availability, safety confidence, and why established pathways still dominate current care.
- Reviewer - Reviewed 2026-04-25Clomid vs TRT for fertility-preserving men: preserving axis versus direct replacementHow clomiphene and TRT compare for men balancing symptom relief with fertility preservation, including mechanism, trade-offs, and monitoring requirements.
Protocol09
- Reviewer - Reviewed 2026-04-29PCOS metabolic and hormonal stackHow ALUKARD structures PCOS care: confirmed phenotype, insulin-first metabolic base with inositol and lifestyle, then a re-measure-and-decide cycle and androgen recheck.
- Author - Reviewed 2026-04-29Insulin resistance reversal stackHow ALUKARD structures pre-diabetes and metabolic-syndrome reversal: HOMA-IR-driven phenotype, structured lifestyle compression, and a 16-24 week decision point before GLP-1.
- Reviewer - Reviewed 2026-04-29Sleep and cortisol recovery stackHow ALUKARD structures sleep and cortisol recovery: 14-day baseline, CBT-I-aligned stimulus control, full HPA panel, and a re-measure-and-personalize phase before any sedatives.
- Reviewer - Reviewed 2026-04-29VO2max progression and Zone-2 stackHow ALUKARD structures VO2max progression: baseline measurement, polarized Zone-2 base, polarized interval blocks, and a 12-16 week retest target.
- Author - Reviewed 2026-04-29Sarcopenia and lean-mass preservation stackHow ALUKARD structures sarcopenia prevention: DEXA + grip baseline, protein floor, progressive resistance training, creatine support, and re-measurement at 16-24 weeks.
- Reviewer - Reviewed 2026-04-27GLP-1 + muscle-preserving weight-loss stackHow ALUKARD structures GLP-1 care: eligibility, dose ramp, muscle-preserving training, lab cadence, and maintenance planning after active loss.
- Reviewer - Reviewed 2026-04-27TRT optimization and safety stackA monitored TRT pathway: two-draw eligibility, dose titration, fertility considerations, and quarterly safety labs to reduce avoidable complications.
- Reviewer - Reviewed 2026-04-27Post-GLP-1 maintenance stackA structured transition after GLP-1: taper planning, appetite-rebound control, coaching cadence, and lab-guided maintenance to reduce regain risk.
- Author - Reviewed 2026-04-27Hair-regrowth and hormonal root-cause stackA provider-reviewed hair protocol that combines DHT strategy, ferritin and thyroid workup, adherence tracking, and objective monthly response checks.